Skip to main content
Marvel Biosciences Corp. logo

Marvel Biosciences Corp. — Investor Relations & Filings

Ticker · MRVL ISIN · CA57384M1077 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 203 across all filing types
Latest filing 2022-10-04 Regulatory Filings
Country CA Canada
Listing TSXV MRVL

About Marvel Biosciences Corp.

https://marvelbiotechnology.com/

Marvel Biosciences Corp. is a pre-clinical stage biotechnology company specializing in the discovery and development of transformative treatments for complex neurological and neurodevelopmental disorders, including Autism Spectrum Disorder, Rett Syndrome, and Fragile X Syndrome. The company's core strategy involves chemical innovation to create synthetic derivatives of existing approved molecules. This drug redevelopment approach leverages established mechanisms to accelerate development and reduce risk. Its lead candidate, MB-204, is a patented synthetic derivative that has demonstrated preclinical efficacy across these target indications and is currently advancing toward first-in-human studies.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from Marvel Biosciences highlighting recent research related to the serotonin theory of depression and their lead drug candidate MB204. It discusses scientific study results, pre-clinical data, and forward-looking statements about the drug's potential. There is no indication of financial results, regulatory filings, management changes, or shareholder voting information. The document is a corporate news release focused on scientific and product development updates rather than a formal financial or regulatory report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2022-10-04 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a news release announcing the grant of stock options to directors and officers of Marvel Biosciences Corp. It details the number of options, exercise price, vesting schedule, and related information. There is no financial report, earnings data, or detailed financial statements. The content focuses on a capital-related event (stock option grants) approved by the board. The document length is under 5,000 characters and is a typical announcement of a financing-related corporate action. Therefore, it fits best under Capital/Financing Update (CAP).
2022-09-26 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a news release from Marvel Biosciences highlighting recent research related to their lead asset MB-204 targeting NASH and Alzheimer's Disease. It contains no financial data, no regulatory form references, no meeting or voting information, no management or board changes, no earnings or interim report data, and no capital or financing updates. The document is a general corporate news announcement about research progress and future plans, typical of a press release. It does not fit into any specific detailed filing category such as Annual Report, Earnings Release, or Investor Presentation. Given its nature as a news release without substantive financial or regulatory content, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements and press releases.
2022-08-31 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings Classification · 100% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about securities distribution, including issuer information, distribution dates, purchaser details, types of securities distributed, and exemptions relied upon. It is a regulatory filing related to exempt distributions of securities, which is a compliance and disclosure document rather than a financial report, earnings release, or management discussion. The form is a standard regulatory filing used in Canadian securities regulation to report exempt distributions. It does not contain financial statements, audit opinions, or management commentary typical of annual or interim reports. It is not an announcement of a report but the report itself, specific to regulatory compliance. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-08-17 English
Material change report - English.pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate, signed by the CFO certifying the review and fair presentation of interim financial reports and MD&A for the period ended June 30, 2022. It is primarily an officer certification letter confirming the accuracy and completeness of interim filings, without containing actual financial statements or substantive financial data. According to the CERTIFICATION RULE, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (2991 characters) and it is a certification, not the report itself.
2022-08-17 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a news release announcing a scientific milestone related to a novel formulation of a drug asset (MB-204) by Marvel Biosciences Inc. It contains no financial data, no regulatory form references, no voting results, no management changes, no earnings or financial statements, and no detailed investor presentation. The document is short (4007 characters) and primarily serves as a corporate update or press release about product development progress. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is not a report publication announcement since it does not mention any report being attached or published. The content is best classified as a general regulatory announcement or corporate news update, which falls under Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories.
2022-07-21 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.